Amid today’s geopolitical tensions, supply chain vulnerability is emerging as an increasingly central concern, and, in the case of life science consumables, one that places the health of the public at risk. The issue itself, however, is far from new.
In December 2020 during the COVID-19 pandemic the FDA added pipette tips to its medical device shortage list [1]. By that spring, about 30% of pathologists surveyed could no longer reliably obtain them [2], compromising patient diagnosis nationwide.
Though the industry has since shifted from efficiency toward supply chain resilience, many labs still depend on imported consumables from overseas suppliers.
This raises a key question: Should the United States reshore life science consumable manufacturing?
For essential life science consumables such as reagents, sterile plastics, culture media, basic Active Pharmaceutical Ingredients (APIs), and critical lab supplies, the answer is yes. However, the remainder should continue to be sourced from a diversified set of suppliers abroad.
Why Reshore Lab Consumable Manufacturing?
Over reliance on foreign hubs for lab consumable manufacturing leaves the U.S. vulnerable to pandemics, logistics disruptions, and other unexpected circumstances. Reliable access to lab consumables is highly important given its direct effects on public health. Federal policy now treats the public-health industrial base as a critical sector and has already begun efforts to reshore its manufacturing. In 2021 the Department of Health and Human Services put over $18 billion toward domestic manufacturing capacity for protective equipment, essential medicines, and medical devices [3].
Bringing lab consumable manufacturing back to the U.S. would also provide the support needed to continue innovation on American soil. The Department of Commerce states that “ultimately, volume drives both innovation and operational learning; in the absence of the commercial volume, the United States will not be able to keep up […] with the technology, in terms of quality, cost, or workforce” [4].
The Technical Challenge of Reshoring
While a pipette tip may seem like a simple disposable attachment, it is actually a precision part. Molding it a few microns out of spec breaks its seal against the pipette barrel, and a bad seal delivers the wrong volume, which at the microliter scale is enough to change a result. The plastic also has to be extremely clean. Trace mold-release agents can leach into a sample and inhibit a PCR reaction, which is why research-grade tips are certified free of DNase, RNase, and human DNA and tested lot by lot. Other consumables are no exception. Microplate well geometry and the clarity of the plate bottom decide whether a user receives a clean signal, and a slightly warped plate will throw off automated imaging [5].
Building the capability to meet these tolerances is both capital and time intensive. Cleanroom construction for the sector runs $200 to $800 per square foot [6], and the construction is the straightforward part. Installation, operational, and performance qualification, plus the quality systems and ISO-class controls regulators expect, stretch the timeline from groundbreaking to first validated lot into years [5].
The Economics of Reshoring
Industry surveys point to high labor and operational costs, along with a shortage of domestic skilled workers, as leading economic barriers to bringing manufacturing back to the U.S. [7]. Additionally, a fully domestic facility still often depends on foreign suppliers for its raw materials and equipment [8].
Market structure works against reshoring as well. For commodity consumables, buyers rarely pay a premium for domestic production, so competition drives prices down until they no longer support the investment that reshoring requires.
For these reasons, reshoring efforts deliver the most value when concentrated where dependence is most dangerous and substitution hardest, rather than spread across the entire category.
A Hybrid Path Forward
The most effective strategy is therefore neither full reshoring nor continued dependence on a narrow set of foreign suppliers. It is a hybrid one. The essential consumables that public health depends on, reagents, sterile plastics, culture media, basic APIs, and critical lab supplies, should be manufactured domestically, with that investment reaching back into the resin and tooling that feed production rather than stopping at the final molding step. The remaining commodity items, such as standard tips and plates, can continue to be sourced internationally.
Sourcing them abroad, however, does not mean depending on any single country. A resilient supply base can be spread across China-plus-one arrangements, friend-shoring to allied economies, and regional production under the USMCA that draws on the combined strengths of the U.S., Canada, and Mexico [9]. This mirrors the broader shift now reshaping Western manufacturing, away from single-source efficiency and toward regional resilience.
How Do We Get There?
The policy tools to support this transition already exist and do not need to be heavy-handed. Federal purchasing power can guarantee steady, long-term demand for domestic producers, giving them the confidence to invest [10]. The room to do so is there, with up to half of U.S. manufacturing capacity currently sitting idle [11]. Faster and more predictable regulatory review would lower the cost and uncertainty of building domestically.
The Bottom Line
The technical timelines, the workforce gap, and the economics of commodity production all point the same way. The U.S. should begin with the essential consumables where dependence carries the greatest risk to public health, build the capability and workforce from there, and maintain a diversified international supply base for the commodity items throughout. Reliable access to the tools of modern biology is too important to leave to a supply chain that breaks under pressure.
Author Bio
